BNR

Burning Rock Biotech Ltd BNR

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,562 of 2,925

Why it scores 27Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$77.16M

Quarter to Dec 31

Net income

$-7.92M

Quarter to Dec 31

Free cash flow

$-4.82M

Quarter to Dec 31

Operating margin

-10.2%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$14.70M total
Kynam Capital Management, LP
$10.52M+0.9%
CRCM LP
$1.77M-24.8%
RENAISSANCE TECHNOLOGIES LLC
$442.3K+49.2%
MORGAN STANLEY
$364.9K+185.5%
Nikko Asset Management Americas, Inc.
$257.7K-1.4%
Sumitomo Mitsui Trust Holdings, Inc.
$248.8K-1.4%
BANK OF AMERICA CORP /DE/
$244.1K0.0%
CITADEL ADVISORS LLC
$236.6K+54.4%
SC CHINA HOLDING Ltd
$177.5K0.0%
UBS Group AG
$150.0K+4291.2%
Almanack Investment Partners, LLC.
$135.6KNew
XTX Topco Ltd
$118.1KNew
BNP PARIBAS FINANCIAL MARKETS
$23.4K0.0%
Tower Research Capital LLC (TRC)
$10.4K+4335.7%
JPMORGAN CHASE & CO
$1.3K-11.2%
ROYAL BANK OF CANADA
$1.0KNew
BlackRock, Inc.
$330.0%
See all 17 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Debt/Equity

FY 2025
EDGAR

Loading ratio trend…

BNR key financials by period

Reported revenue, net income and operating margin by fiscal year, from Burning Rock Biotech Ltd's annual filings on SEC EDGAR.

Burning Rock Biotech Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$77.2M$-7.9M-10.2%
FY 2024$70.7M$-47.5M-69.3%
FY 2023$75.7M$-92.1M-124.5%
FY 2022$81.7M$-140.8M-174.1%
FY 2021$79.7M$-125.0M-156.9%
FY 2020$65.9M$-62.4M-95.9%
Source: BNR filings on SEC EDGAR →

Companies similar to BNR

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

BNR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Burning Rock Biotech Ltd (BNR): stock profile, AI score and financials

Burning Rock Biotech Ltd (BNR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BNR at 27.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,562 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Burning Rock Biotech Ltd reports quarterly revenue of $77.2M, net income of $-7.9M, an operating margin of -10.2%. Top institutional holders of BNR by reported 13-F value include Kynam Capital Management, CRCM, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. BNR trades on the Nasdaq exchange and files with the SEC under CIK 1792267. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Burning Rock Biotech Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 1792267 →